top of page
Dynamic Drug Advancement Limited | Durham Institute of Respirology
About the Trial
This Phase IIb dose-ranging study will evaluate the efficacy and safety of 3 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.
Mechanism of Action:
IRAK4 Inhibitor
Duration of Study
~26 weeks
Phase
IIb
Principal Investigator
Dr. George Philteos
Sub-Investigator
Dr. Anushya Chelvanathan
Study Coordinator
Cynthia Lee
bottom of page